Roche Holding AG (LTS:0QQ6) Debt-to-Asset : 0.36 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Roche Holding AG Debt-to-Asset?

Roche Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF6,021 Mil. Roche Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was CHF28,420 Mil. Roche Holding AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was CHF95,786 Mil. Roche Holding AG's debt to asset for the quarter that ended in Jun. 2024 was 0.36.

Roche Holding AG Debt-to-Asset Historical Data

The historical data trend for Roche Holding AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Debt-to-Asset Chart

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.19

0.18

0.35

0.30

0.34

Roche Holding AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.32	0.30	0.30	0.34	0.36

Competitive Comparison of Roche Holding AG's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Roche Holding AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Debt-to-Asset falls into.

Roche Holding AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Roche Holding AG's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4691	+	26091)	/	90468
	=	0.34

Roche Holding AG's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6021	+	28420)	/	95786
	=	0.36

Roche Holding AG (LTS:0QQ6) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Roche Holding AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (LTS:0QQ6) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0TDF:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG Headlines

No Headlines